16 results about "Emtricitabine" patented technology

The invention relates to the technical field of pharmaceutical analysis, and particularly discloses a high performance liquid chromatography-mass spectrometry tandem method (HPLC-MS / MS) for detecting a genotoxic impurity L-alanine isopropyl ester in an emtricitabine-propofol tenofovir tablet. By optimizing chromatographic column selection, a mobile phase gradient elution procedure and mass spectrometric detection parameters, the method realizes exclusive, sensitive and accurate detection of the L-isopropyl alanine. The methodological verification result shows that the detection limit is 1.00 ng / mL, the quantification limit is 2.00 ng / mL, the linear range is 2.00-100.00 ng / mL (the correlation coefficient r is equal to 0.9994), the recovery rate is stabilized between 92% and 98%, and the precision and repeatability are good. The detection method has the advantages of high sensitivity and strong selectivity, is suitable for quality control of emtricitabine propofol tenofovir tablets, meets the control requirements of ICH M7 guide on genotoxic impurities, and has good practicability and popularization value.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of drug analysis and detection, and particularly discloses a method for detecting related substances in emtricitabine, propiophenol and tenofovir disoproxil fumarate tablets. According to the method, an octadecyl silane bonded silica gel chromatographic column is adopted, a mixed solution of a phosphate buffer solution and a tetrahydrofuran-acetonitrile solution in different volume ratios is taken as a mobile phase A and a mobile phase B respectively, and a gradient elution mode is adopted by a dual-wavelength high-performance liquid chromatography; the method can realize effective separation of a plurality of impurities in the emtricitabine, propofol and tenofovir disoproxil fumarate tablet, and accurately detect the condition of the impurities in the emtricitabine, propofol and tenofovir disoproxil fumarate tablet. The methodology research and verification of specificity, sensitivity and the like of the method provided by the invention find that the method provided by the invention is sensitive, accurate and relatively good in reproducibility, and accurate and quantitative detection of the related substances in the emtricitabine, propofol and tenofovir disoproxil tablet can be realized by using a simple, convenient and rapid method; and a reliable guarantee is provided for improving and better controlling the quality of the emtricitabine, propofol and tenofovir disoproxil fumarate tablet product.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

1. Name of the design product: packaging box (metformin hydrochloride and pioglitazone hydrochloride tablet). 2. Use of the design product: the design product is used for the packaging of medicines. 3. Design points of the design product: the combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt theroof, and emtricitabine or a pharmaceutically acceptable salt thereof.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The application discloses a preparation method of an intermediate of entecavir, and the intermediate is prepared from dimethyl oxalate through four steps of amidation, ring closure, reduction and chlorination to obtain 3-(chloromethyl)-1-methyl-1 H -1,2,4-triazole hydrochloride with high purity. The application has the advantages of mild reaction condition, simple operation, high yield, low cost and suitability for industrial production.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.